Biofrontera

Biofrontera, Inc. is a biopharmaceutical company, which engages in the commercialization of pharmaceutical products. It specializes in the treatment of dermatological conditions, caused primarily by exposure to sunlight that results in sun damage to the skin. The company is focused on the treatment of actinic keratosis and markets a topical antibiotic for treatment of impetigo. Its products include Ameluz and Xepi, its two prescription drugs, and BF-RhodoLED, a lamp used with Ameluz, for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company was founded on March 3, 2015 and is headquartered in Woburn, MA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biofrontera reports Q1 recovery post cyberattack, eyes product expansion

Biofrontera Inc. navigated challenges in Q1 2024, with a cyberattack impacting revenues, but recovery and growth were evident by April 30, 2024.
The company's strategic strengths lie in cost reduction through renegotiations, successful fundraising efforts, and advancements in clinical trials and product development.
Opportunities abound for Biofrontera with upcoming product launches, FDA approvals, and a focus on operational efficiency and financial management to drive future profitability.
Addressing financial challenges and leveraging opportunities will be key for Biofrontera to sustain growth, enhance market position, and deliver value to stakeholders in the coming quarters.

Biofrontera reports robust Q2 sales growth and cost efficiencies

Biofrontera delivered strong sales growth and cost management in Q2 2024, improving financial performance.
While challenges like net losses persist, opportunities exist to leverage momentum for sustained growth.
The company's focus on operational efficiency and revenue expansion sets the stage for future success and value creation.

Biofrontera reports steady Q3 growth amidst operational challenges and opportunities

Biofrontera Inc. showed resilience with revenue growth despite challenges like delayed deliveries.
Strategic strengths include FDA approvals, positive trial results, and focus on operational efficiency.
Challenges in high operating expenses and negative EBITDA highlight areas for improvement.
Opportunities lie in market expansion, clinical trial progress, and strategic financial management.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Named A mong the 10 Fastest - Growing Life Sciences Companies to Watch in 2022 by CIOCoverage Magazine

Biofrontera, Inc. Recognized for Rapid Sales Growth, Innovative Therapies and Marketing Excellence

WOBURN, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the Company will be participating in The Benchmark Healthcare House Call Virtual 1x1 Conference being held on June 2, 2022.

Biofrontera Inc. to Participate in The Benchmark Healthcare House Call Virtual 1x1 Conference

WOBURN, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, views new data on skin cancer prevalence provided by the American Cancer Society1, indicating approximately 3.4 million U.S. residents could be diagnosed with non-melanoma skin cancer (NMSC) in 2022, as strongly supportive of the commercial opportunity for the Company's flagship product Ameluz®. Additionally, a market survey report published earlier this month by ReportLinker2, titled “Global Non-melanoma Skin Cancer Market 2022-2026,” forecasts the global NMSC market will grow by more than $180 million during that period. The report identifies the increasing incidence of NMSC as a primary driver of market growth, forecasting a compound annual growth rate of 5.8% through 2026.

New Data and Forecasts for the U.S. Skin Cancer Market Strongly Support the Commercial Opportunity for Biofrontera's Ameluz®

WOBURN, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) , a biopharmaceutical company specializing in the commercialization of dermatological products, announced today the closing of its previously-announced $9.4 million private placement with a single institutional investor.

Biofrontera Inc. Announces Closing of $9.4 Million Private Placement

Biofrontera, Inc. (NASDAQ:BFRI ) Q1 2022 Results Conference Call May 13, 2022 11:00 AM ET Company Participants Tirth Patel - LHA IR Hermann Lubbert - Executive Chairman Erica Monaco - CEO Operator Good morning and welcome to the Biofrontera Inc's First Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Biofrontera, Inc. (BFRI) CEO Erica Monaco on Q1 2022 Results - Earnings Call Transcript

WOBURN, Mass., May 06, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, will report financial results for the three months ended March 31, 2022 before the opening of the U.S. financial markets on Friday, May 13, 2022 and will hold a conference call that same day beginning at 11:00 a.m. Eastern time to discuss those results, provide a business update and answer questions.

Biofrontera Inc. to Report First Quarter Financial Results on May 13, 2022

Live Demonstration of New RhodoLED ® XL to be Featured

Biofrontera Inc. to Showcase Actinic Keratosis Treatments at the Music City Symposium for Cosmetic Advances & Laser Education

Ameluz® for the treatment of actinic keratoses now at www.ameluz.com Xepi® for the treatment of impetigo now at www.xepicream.com

Biofrontera Launches New Patient-Focused Websites for Ameluz® and Xepi®

Significantly Improves Manufacturing Efficiency , Quality Control and Supply Reliability

Biofrontera Inc. Announces FDA Approval of Biofrontera Pharma GmbH as a Contract Laboratory for Ameluz®

Aterian

Lyra Therapeutics

Medavail Holdings Inc

ENDRA Life Sciences

We're diving into the top penny stocks for today in our market update for Friday with all the latest news that's moving shares! The post Top Penny Stocks Today: Why ATER, BFRI, NDRA, MDVL and LYRA Stocks Are Soaring Friday appeared first on InvestorPlace.

Top Penny Stocks Today: Why ATER, BFRI, NDRA, MDVL and LYRA Stocks Are Soaring Friday

I ntroduces 2022 financial guidance Conference call begins at 11 :0 0 a .m. Eastern time today

Biofrontera Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Business Update

WOBURN, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today preliminary, unaudited product revenues for the quarter ended March 31, 2022.

Biofrontera Inc. Announces Preliminary Product Revenues for the First Quarter of 2022

WOBURN, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today it will report financial results for the three months and full year ended December 31, 2021 before the opening of the U.S. financial markets on Friday, April 8, 2022 and will host a conference call that same day beginning at 11:00 a.m. Eastern time to discuss those results, provide a business update and answer questions.

Biofrontera Inc. to Report Fourth Quarter and Full Year 2021 Financial Results on April 8, 2022

Company to have a strong onsite presence at the world's l argest scientific conference for dermatologists, with approximately 10,000 medical professionals expected to attend

Biofrontera to Showcase Actinic Keratoses and Impetigo Treatments at the 2022 American Academy of Dermatology Annual Meeting

WOBURN, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI ) , a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the previously granted U.S. patent No. 11,235,169 (the '169 patent) for the BF-RhodoLED® XL illumination device is now listed in the U.S. Food and Drug Administration (FDA) publication “Approved Drug Products with Therapeutic Equivalence Evaluations,” commonly known as the Orange Book.

Biofrontera Inc. Announces FDA Orange Book Listing of U.S. Patent for BF-RhodoLED® XL, Extends Protection of Ameluz®-PDT Through October 2040

WOBURN, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, announces today that Erica Monaco, Chief Executive Officer, will be presenting and meeting with registered investors at the 34th Annual Roth Conference being held March 13-15 in Laguna Niguel, California.

Biofrontera Inc. to Present at the 34th Annual Roth Conference

WOBURN, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, announces the appointment of Kevin D. Weber to its Board of Directors, expanding Board membership to five Directors.

Biofrontera Inc. Appoints Kevin D. Weber to its Board of Directors

Vinco Ventures

Cassava Sciences Inc

Sirius XM Holdings Inc

Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.

5 Short Squeeze Candidates To Watch: Vinco Ventures, TSR, Biofrontera And More

Bit Digital, Inc

Hive Blockchain Technologies Ltd

Indonesia Energy Corp Ltd

Mind Medicine MindMed

Reddit penny stocks to watch in February. The post 5 Penny Stocks To Buy Right Now According To Reddit Social Sentiment appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks To Buy Right Now According To Reddit Social Sentiment

Outlook Therapeutics Inc

Spectrum Pharma

Are these on your list of penny stocks to watch right now? The post 3 Top Penny Stocks To Buy For Under $5 Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Top Penny Stocks To Buy For Under $5 Today

WOBURN, Mass., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, is pleased to provide an update on the patient recruitment for the phase III clinical study for the treatment of superficial basal cell carcinoma (sBCC) with Ameluz® photodynamic therapy (Ameluz®-PDT) in combination with the BF-RhodoLED® lamp in the U.S. To date, 70% of the planned 186 patients have been enrolled in the study. Patient recruitment for this study has been ongoing since 2018 with completion of patient recruitment anticipated by the end of 2022.

Biofrontera Inc. provides Update on Patient Recruitment for Phase III Study for the Treatment of sBCC with Ameluz®-PDT

WOBURN, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, today issued the following letter from CEO Erica Monaco and Executive Chairman of the Board Hermann Lübbert.

Biofrontera Inc. Issues Letter to Shareholders Highlighting 2021 Successes and Key Elements of the Strategic Plan for 2022 and Beyond

WOBURN, Mass., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced preliminary, unaudited revenue for the quarter and full year ended December 31, 2021.

Biofrontera Inc. Announces Preliminary Revenue for the Fourth Quarter and Full Year 2021

WOBURN, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that it plans to participate in the following two dermatology conferences in January:

Biofrontera Inc. Announces Participation in Two Dermatology Conferences in January

WOBURN, Mass., Dec. 30, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced that through the exercise of outstanding warrants the majority ownership of Biofrontera AG was diluted below 50%. Biofrontera AG's shareholding in Biofrontera Inc. of 8,000,000 shares is unchanged, but now represents approximately 47% of the currently outstanding shares. As a result, Biofrontera Inc. is no longer considered a subsidiary of Biofrontera AG. Biofrontera Inc.'s common stock and warrants are traded on the Nasdaq Capital Market under the ticker symbols “BFRI” and “BFRIW,” respectively.

News for Biofrontera Stock (BFRI)